DGAP-News: Evotec and The Leukemia&Lymphoma Society enter into a strategic research collaboration
(firmenpresse) - DGAP-News: Evotec AG / Key word(s): Alliance
Evotec and The Leukemia&Lymphoma Society enter into a strategic
research collaboration
05.11.2013 / 07:29
---------------------------------------------------------------------
Hamburg, Germany - 05 November 2013: Evotec AG (Frankfurt Stock Exchange:
EVT, TecDAX, ISIN: DE0005664809) announced today that it has entered into
an integrated research collaboration with The Leukemia&Lymphoma Society
('LLS'). Evotec will support one of LLS's Screen-to-Lead Programs ('SLP').
In this collaboration, Evotec partners with LLS to support selected
programmes and principal investigators with resources for high-throughput
screening and optimisation of small molecules into drug-like compounds.
Evotec delivers an industrialised, cutting-edge, comprehensive and unbiased
drug discovery infrastructure to support innovation efficiency as part of a
fully integrated solution.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: 'We are
excited to initiate this collaboration and support The Leukemia and
Lymphoma Society and their investigators. We are confident that our
experienced scientists and innovation platform can deliver results for LLS,
their investigators and ultimately patients.'
Amy Burd, Ph.D., Executive Director of Research at LLS, added: 'LLS is
pleased to be working in collaboration with Evotec to advance our
Screen-to-Lead programs. We feel that Evotec has the necessary skills and
capabilities to offer significant value to support these projects.'
No financial details were disclosed.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing
the highest quality stand-alone and integrated drug discovery solutions,
covering all activities from target-to-clinic. The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology and inflammation. Evotec has
long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca
and Ono Pharmaceutical. In addition, the Company has existing development
partnerships and product candidates both in clinical and pre-clinical
development. These include partnerships with Boehringer Ingelheim,
MedImmune and Andromeda (Teva) in the field of diabetes, with Janssen
Pharmaceuticals in the field of depression and with Roche in the field of
Alzheimer's disease. For additional information please go to www.evotec.com
ABOUT LEUKEMIA AND LYMPHOMA SOCIETY
The Leukemia&Lymphoma Society (LLS) is the world's largest voluntary
health agency dedicated to blood cancer. The LLS mission: Cure leukemia,
lymphoma, multiple myeloma, and improve the quality of life of patients and
their families. LLS funds lifesaving blood cancer research around the
world, provides free information and support services, and is the voice for
all blood cancer patients seeking access to quality, affordable,
coordinated care.
Founded in 1949 and headquartered in White Plains, NY, LLS has chapters
throughout the United States andCanada. To learn more, visit www.LLS.org.
Patients should contact the Information Resource Center at (800) 955-4572,
Monday through Friday, 9 a.m. to 6 p.m. ET.
FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.
Contact Evotec AG:
Gabriele Hansen, Head of Corporate Communications, Phone:
+49.(0)40.56081-255, gabriele.hansen(at)evotec.com
End of Corporate News
---------------------------------------------------------------------
05.11.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info(at)evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
237782 05.11.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 05.11.2013 - 07:29 Uhr
Sprache: Deutsch
News-ID 312559
Anzahl Zeichen: 21294
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 331 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Evotec and The Leukemia&Lymphoma Society enter into a strategic research collaboration"
steht unter der journalistisch-redaktionellen Verantwortung von
Evotec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
